# US 2019/0167727 A1 · Neuroprotective composition, preparation process thereof and medical uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167727 A1
- Document ID: US20190167727A1
- Status: Published application
- Kind: A1
- Application number: 16/106,290
- Filed: 2018-08-21
- Published: 2019-06-06
- Earliest claimed: 2017-12-04
- Assignees: Caire Medical-Biotechnology International Co.
- Applicants: Caire Medical-Biotechnology International Co.
- Inventors: Te-Fu CHEN; Kuo-Chuan WANG
- Web page: https://patentgrep.com/patent/US20190167727A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/26: Psychostimulants, e.g. nicotine, cocaine
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C12N 5/0664: {Dental pulp stem cells, Dental follicle stem cells}
- C12N 2502/1364: Dental pulp stem cells, dental follicle stem cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to a neuroprotective composition derived from mesenchymal stem cells, especially a neuroprotective composition derived from the primary culture of dental pulp mesenchymal stem cells. The invention also relates to a process for preparing the neuroprotective composition, as well as the medical use of the neuroprotective composition in the treatment of Parkinson's disease.

## Claims

### Claim 1

A method for treating Parkinson's disease in a subject, comprising administering to said subject an effective amount of a neuroprotective composition to suppress neuronal damage; wherein the neuroprotective composition is obtainable by a process comprising the steps of:
(i) culturing mesenchymal stem cells in a serum-free basal culture medium for at least 3 hours to obtain a cell culture; and
(ii) processing the cell culture obtained in step (i) to obtain an aqueous fraction with a molecular weight of no more than about 5 kDa as the neuroprotective composition.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the mesenchymal stem cells are dental pulp mesenchymal stem cells.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the processing step (ii) comprises ultrafiltrating the cell culture obtained in step (i) through a membrane having a molecular weight cut-off of 5 kDa, thereby collecting a filtrate passing through the membrane.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the subject is selected from the group consisting of human and non-human vertebrates.